Introduction
Scleroderma develops when the immune system, blood vessels, and connective tissue begin to behave abnormally at the same time. In its simplest form, what causes scleroderma is not one single event but a combination of biological processes that lead to immune activation, damage to small blood vessels, and excessive production of collagen and other structural proteins. The result is hardening and thickening of skin and, in some forms of the disease, injury to internal organs. The condition is thought to arise from a mix of autoimmune activity, genetic susceptibility, and environmental or hormonal triggers that disturb normal tissue repair.
Because scleroderma is a complex connective tissue disease, its causes are best understood in categories: the underlying biological mechanisms, the primary triggers most strongly linked to disease development, additional risk factors that increase vulnerability, and other medical conditions that may contribute to or reveal the process.
Biological Mechanisms Behind the Condition
The core biological problem in scleroderma is an abnormal repair response. Under normal circumstances, when tissue is injured, inflammation helps clear damage, immune cells coordinate repair, and fibroblasts produce temporary collagen to restore structure. Once healing is complete, the process shuts down. In scleroderma, that sequence does not turn off properly. Immune signaling remains active, small blood vessels are damaged, and fibroblasts keep producing collagen as if the body were continuously repairing an injury that never resolves.
This leads to fibrosis, the excessive buildup of scar-like connective tissue. Fibrosis is not just a passive accumulation; it is driven by signaling molecules such as transforming growth factor beta, interleukins, and other cytokines that stimulate fibroblasts to become overactive. These cells behave more like wound-healing cells than normal maintenance cells. They deposit collagen in skin and sometimes in the lungs, digestive tract, heart, or kidneys, making tissues thicker, less elastic, and less functional.
Another major component is vascular dysfunction. The small arteries and capillaries that supply tissue become narrowed or injured, partly because of immune-mediated damage to the endothelium, the thin inner lining of blood vessels. When endothelial cells are harmed, they release fewer protective substances and more signals that promote vessel constriction and inflammation. Reduced blood flow worsens tissue stress and may further stimulate fibrosis. In this way, vascular injury and collagen overproduction reinforce each other.
Autoimmunity is also central. Many people with scleroderma produce autoantibodies, which are antibodies directed against the body’s own structures. These autoantibodies do not simply mark the disease; they reflect a loss of immune tolerance and may participate in the inflammatory cascade that drives tissue injury. The exact sequence that starts the process is still being studied, but the disease clearly involves an immune system that has shifted from protection to self-directed attack.
Primary Causes of Scleroderma
There is no single cause that explains every case of scleroderma, but several mechanisms are repeatedly implicated. The strongest associations involve autoimmune dysregulation, endothelial injury, and abnormal activation of fibroblasts. These are better understood as biological drivers than as isolated causes, because each one influences the others.
Autoimmune dysfunction is one of the most important factors. In scleroderma, the immune system appears to lose tolerance to normal body tissues. T cells, B cells, and antibody-producing pathways become activated in ways that support chronic inflammation. This immune activity can damage vessels and stimulate fibroblasts through cytokines and growth factors. The presence of specific autoantibodies in many patients suggests a misdirected adaptive immune response that is part of the disease process, not merely a bystander finding.
Endothelial injury is another major cause at the tissue level. The endothelial lining of small blood vessels becomes damaged early in the disease, reducing circulation and impairing normal vascular regulation. This injury may occur from immune attack, oxidative stress, toxins, or other triggers. Once the endothelium is compromised, the body responds with inflammatory and repair signals. Instead of restoring normal vessel function, these signals can promote further narrowing of vessels and encourage fibrosis. The result is a cycle of poor blood flow and progressive tissue hardening.
Fibroblast overactivation is the direct mechanism responsible for collagen accumulation. Fibroblasts are normal connective tissue cells that produce collagen and other extracellular matrix proteins. In scleroderma, they become persistently activated by immune mediators and damage signals. They continue laying down collagen even when no meaningful repair is needed. Over time, this excessive matrix production alters tissue architecture and function. In the skin, it creates stiffness and thickening; in internal organs, it can impair gas exchange, motility, filtration, or cardiac function depending on the tissue involved.
In some individuals, microchimerism may also play a role. This refers to the presence of a small number of cells from another individual, often acquired during pregnancy. These foreign cells may stimulate immune responses in genetically susceptible people, although this mechanism is still being investigated and does not explain most cases. It is best viewed as a possible contributor to immune activation rather than a universal cause.
Contributing Risk Factors
Several factors can increase the likelihood that these biological processes will begin. They do not cause scleroderma on their own in most cases, but they can create a context in which immune and connective tissue abnormalities are more likely to develop.
Genetic influences are important. Scleroderma is not usually inherited in a simple pattern, but certain gene variants appear to increase susceptibility. Many of these genes are involved in immune regulation, antigen presentation, and inflammatory signaling. If these pathways are less effective at maintaining self-tolerance, the immune system may be more likely to mount a pathologic response against the body’s own tissues. Genetics also affects how strongly a person responds to environmental triggers, which helps explain why only some exposed individuals develop disease.
Environmental exposures are among the most studied risk factors. Silica dust, certain organic solvents, and some industrial chemicals have all been associated with increased risk. These exposures may damage endothelial cells, promote oxidative stress, or alter immune signaling. For example, inhaled silica can provoke persistent inflammation and immune activation, while solvents may interfere with normal cellular repair pathways. These effects do not produce scleroderma directly in every exposed person, but they may push susceptible immune and vascular systems toward chronic dysfunction.
Infections have been considered as possible triggers, though the evidence is less direct than for autoimmune and environmental mechanisms. Some infections may activate the immune system in a way that leads to molecular mimicry, where immune responses intended for a pathogen cross-react with self-antigens. Other infections may simply create prolonged inflammation that destabilizes immune regulation. The infection itself is usually not the cause of long-term scleroderma, but it may help initiate the abnormal immune response in vulnerable individuals.
Hormonal factors are also relevant. Scleroderma is more common in women, suggesting that sex hormones or sex-linked immune differences may influence susceptibility. Estrogen and related hormonal pathways affect immune cell activity, antibody production, and vascular function. These influences may help explain why the disease is more frequent in women and why hormonal changes could alter disease risk or expression. The relationship is complex and not fully understood, but it likely reflects hormonal effects on immune regulation rather than a simple endocrine cause.
Lifestyle and physiological stressors may contribute indirectly. Smoking, for instance, can worsen vascular injury and reduce tissue oxygenation, which may amplify the vascular component of disease. Chronic stress is not considered a direct cause, but long-term neuroimmune effects may alter inflammatory regulation. These influences are generally weaker than autoimmune or genetic factors, yet they can affect disease expression by increasing vascular strain or promoting inflammatory signaling.
How Multiple Factors May Interact
Scleroderma usually develops when several risk factors converge rather than from one isolated cause. A genetically susceptible person may have immune pathways that are already less stable than average. If that person is exposed to a vascular toxin, silica, or another trigger, endothelial cells may be damaged and inflammatory signaling may rise. The immune system then becomes activated, sometimes in a self-perpetuating way, and fibroblasts respond by increasing collagen production. Once this feedback loop begins, the original trigger may no longer be necessary for the disease to continue.
This interaction helps explain why the disease can vary so widely. In one person, vascular injury may be the dominant early event; in another, autoimmunity may be more obvious, with antibody production preceding skin changes. Hormonal status, age-related immune changes, and other health conditions can alter how strongly each pathway is expressed. The final disease pattern reflects the combined effect of these systems rather than a single mechanism acting alone.
Variations in Causes Between Individuals
The causes of scleroderma differ from person to person because susceptibility is shaped by multiple biological layers. Genetics influences baseline immune behavior and how the body handles environmental stress. Age can affect immune regulation and vascular repair, so older individuals may respond differently to the same trigger than younger ones. Overall health also matters: chronic inflammation, vascular disease, or reduced organ reserve can make tissue injury more consequential and recovery less efficient.
Environmental exposure history is another source of variation. A person with substantial occupational exposure to silica or solvents may develop disease through a different initiating pathway than someone whose main risk is autoimmune predisposition. In some cases, reproductive history or hormonal state may also alter risk, especially in women. These differences do not create separate diseases, but they can shape the balance between immune activation, blood vessel injury, and fibrosis, leading to distinct clinical forms and degrees of severity.
Conditions or Disorders That Can Lead to Scleroderma
Certain medical conditions can trigger scleroderma-like changes or contribute to the disease process. The most important of these are other autoimmune disorders and overlap syndromes. People with systemic lupus erythematosus, rheumatoid arthritis, Sjogren syndrome, or mixed connective tissue disease may develop overlapping immune abnormalities that increase the likelihood of scleroderma features. In these settings, the immune system is already misdirected, making additional connective tissue damage more plausible.
Some cases occur in association with autoimmune thyroid disease or other organ-specific autoimmune conditions, which suggests a broader tendency toward loss of self-tolerance. The relationship is physiological: if immune checkpoints are impaired, antibodies and inflammatory cells may target more than one tissue type. This can create a systemic environment favorable to fibrosis and vascular injury.
Rarely, scleroderma-like changes can be seen after certain toxic exposures or as part of related fibrosing disorders. For example, exposure to specific chemicals may provoke immune and vascular injury that resembles scleroderma. In these cases, the associated condition does not always cause classic systemic sclerosis, but it can produce similar fibrotic and vascular mechanisms. The important point is that disorders which chronically activate immunity or injure small vessels can create the physiologic conditions under which scleroderma develops.
Conclusion
Scleroderma is caused by a convergence of abnormal immune activity, vascular injury, and excessive connective tissue repair. The body loses normal control over inflammation and wound healing, leading fibroblasts to deposit too much collagen while small blood vessels become damaged and narrowed. Genetic susceptibility, environmental exposures, hormonal influences, infections, and other autoimmune disorders can all contribute to this process. In some people, one factor is prominent; in others, several influences act together to start and sustain the disease.
Understanding the causes of scleroderma means recognizing that it is not simply a skin disorder but a systemic failure of immune and repair mechanisms. The disease develops when the usual boundaries between healing and scarring break down. That breakdown explains why scleroderma can remain localized in some individuals and become a multi-organ condition in others, and why its origins are best understood through the interplay of biology, environment, and individual susceptibility.